482 related articles for article (PubMed ID: 25523099)
1. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
5. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
Ozel Coskun BD; Yucesoy M; Gursoy S; Baskol M; Yurci A; Yagbasan A; Doğan S; Baskol G
Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):142-9. PubMed ID: 25533429
[TBL] [Abstract][Full Text] [Related]
6. N-3 polyunsaturated fatty acid attenuates cholesterol gallstones by suppressing mucin production with a high cholesterol diet in mice.
Kim JK; Cho SM; Kang SH; Kim E; Yi H; Yun ES; Lee DG; Cho HJ; Paik YH; Choi YK; Haam SJ; Shin HC; Lee DK
J Gastroenterol Hepatol; 2012 Nov; 27(11):1745-51. PubMed ID: 22849613
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
[TBL] [Abstract][Full Text] [Related]
9. Hydroxytyrosol prevents reduction in liver activity of Δ-5 and Δ-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice.
Valenzuela R; Echeverria F; Ortiz M; Rincón-Cervera MÁ; Espinosa A; Hernandez-Rodas MC; Illesca P; Valenzuela A; Videla LA
Lipids Health Dis; 2017 Apr; 16(1):64. PubMed ID: 28395666
[TBL] [Abstract][Full Text] [Related]
10. A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis.
Li H; Wang M; Chen P; Zhu M; Chen L
Biomed Pharmacother; 2024 May; 174():116617. PubMed ID: 38643542
[TBL] [Abstract][Full Text] [Related]
11. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.
Fan JG; Zhong L; Tia LY; Xu ZJ; Li MS; Wang GL
World J Gastroenterol; 2005 Apr; 11(15):2346-50. PubMed ID: 15818751
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
13. Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: role of PPAR-α and SREBP-1c.
Dossi CG; Tapia GS; Espinosa A; Videla LA; D'Espessailles A
J Nutr Biochem; 2014 Sep; 25(9):977-84. PubMed ID: 24993917
[TBL] [Abstract][Full Text] [Related]
14. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.
Nozaki Y; Fujita K; Wada K; Yoneda M; Kessoku T; Shinohara Y; Imajo K; Ogawa Y; Nakamuta M; Saito S; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
BMC Gastroenterol; 2015 Apr; 15():42. PubMed ID: 25881230
[TBL] [Abstract][Full Text] [Related]
15. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
Ali MH; Messiha BA; Abdel-Latif HA
Pharm Biol; 2016 Jul; 54(7):1198-208. PubMed ID: 26134756
[TBL] [Abstract][Full Text] [Related]
17. Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model.
Comeglio P; Sarchielli E; Filippi S; Cellai I; Guarnieri G; Morelli A; Rastrelli G; Maseroli E; Cipriani S; Mello T; Galli A; Bruno BJ; Kim K; Vangara K; Papangkorn K; Chidambaram N; Patel MV; Maggi M; Vignozzi L
J Endocrinol Invest; 2021 Oct; 44(10):2175-2193. PubMed ID: 33586025
[TBL] [Abstract][Full Text] [Related]
18. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
Cha JY; Park JM; Lee HJ; Bae JS; Han YM; Oh BC; Ko KH; Hahm KB
Curr Pharm Des; 2017; 23(27):3941-3951. PubMed ID: 28714405
[TBL] [Abstract][Full Text] [Related]
19. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice.
Honda T; Ishigami M; Luo F; Lingyun M; Ishizu Y; Kuzuya T; Hayashi K; Nakano I; Ishikawa T; Feng GG; Katano Y; Kohama T; Kitaura Y; Shimomura Y; Goto H; Hirooka Y
Metabolism; 2017 Apr; 69():177-187. PubMed ID: 28285648
[TBL] [Abstract][Full Text] [Related]
20. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
